Topical bimatoprost has been shown to cause periorbital changes of soft tissue which are most
pronounced when used directly onto the cornea for the treatment of glaucoma. Changes are
primarily felt to be the result of prostaglandin-mediated adipocyte loss, resulting in
deepening of the upper eyelid sulcus and recession of infraorbital pseudoherniation. Use of
topical bimatoprost to the upper eyelid margin, now FDA approved for eyelash enhancement, may
provide a metered effect on the periocular tissues and allow for a topical approach to
periocular rejuvenation.
This is a proof of concept study which aims to enroll a series of patients with mild to
severe dermatochalasis, treat with topical bimatoprost 0.03% solution to the upper lid
margin, and evaluate for cosmetic improvement of the periocular area.